Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06675136
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 378
- Registration Number
- NCT06616584
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 39
- Registration Number
- NCT06564298
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06542731
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of JFCR, Koto-ku, Japan
🇯🇵Teikyo University Hospital, Itabashi-ku, Japan
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06445972
- Locations
- 🇧🇷
Liga Norte Riograndense Contra o Câncer ( Site 8303), Natal, Rio Grande Do Norte, Brazil
🇺🇸University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona, United States
🇺🇸Norton Cancer Institute - Downtown ( Site 8900), Louisville, Kentucky, United States
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
- Conditions
- Unresectable Esophageal AdenocarcinomaUnresectable Gastric CarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaMetastatic Esophageal CancerMetastatic Gastric CarcinomaMetastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Esophageal AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT06251973
- Locations
- 🇺🇸
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Conditions
- Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 224
- Registration Number
- NCT06203600
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 168
- Registration Number
- NCT06043427
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 146
- Registration Number
- NCT06038578
- Locations
- 🇺🇸
Texas Oncology-Sammons Cancer Center, Dallas, Texas, United States
🇰🇷ASAN Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT06031688
- Locations
- 🇺🇸
Kaiser Permanente-Bellflower, Bellflower, California, United States
🇺🇸Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.